Skip to content
Review Open access

Recent Advances in Mitochondria-Targeted Delivery Strategies for Ischemic Stroke Therapy

Oct 2026 · International Journal of Nanomedicine · Vol 21 · 0 citations · 186 references
Medicine

Abstract

Abstract Ischemic stroke remains a leading cause of death and disability, and mitochondrial dysfunction links bioenergetic failure, oxidative stress, neuroinflammation, blood–brain barrier (BBB) injury, and cell death. Despite extensive preclinical neuroprotection research, translation has often failed because candidate interventions show inadequate brain exposure and mitochondrial target engagement, are tested under pretreatment or simplified experimental conditions, emphasize short-term infarct reduction rather than durable functional recovery, and are difficult to integrate with time-critical reperfusion care. This Review analyzes mitochondria-targeted delivery as a sequential cascade spanning systemic stability, BBB or nose-to-brain entry, lesion and cell selection, endosomal escape, mitochondrial access, and functional rescue. We compare brain-targeted, intranasal, biomimetic, and organelle-transplantation platforms; place recent examples alongside established mitochondria-targeted antioxidant and mitochondrial-transfer literature; and distinguish localization evidence from causal mitochondrial recovery. The most tractable next steps are a standardized, disease-relevant validation framework and simplified delivery designs compatible with acute stroke workflows. Translational success will require integrated systems that address the complete sequential delivery cascade with the minimum necessary complexity, reproducible manufacturing, clinically relevant treatment windows, and long-term functional and safety endpoints.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.